Category

Therapeutic Areas

Home > Therapeutic Areas (Page 21)

Coll P, Jarrín I, Martínez E, Martínez-Sesmero JM, Domínguez-Hernández R, Castro-Gómez A, Casado MA

 

 

Achieving the UNAIDS goals by 2030 in people living with HIV: A simulation model to support the prioritization of health care interventions
Enfermedades Infecciosas y Microbiología Clínica. Doi.org/10.1016/j.eimc.2022.07.012

Esteban R, Domínguez-Hernández R, Martín-Escudero V, Casado MA

 

 

Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain
Plos One. Doi.org/10.1371/journal.pone.0278544

Calvo García A, Chamorro de Vega E, Romero Jiménez R, Fernández Pacheco García-Valdecasas M, Herrero Muñoz N, Muñoz Cuadrado A, Casado Gómez A, Ramírez Herráiz E

 

Evaluación de la calidad de vida percibida por pacientes con enfermedades inflamatorias inmunomediadas en tratamiento con terapias biológicas y pequeñas moléculas dirigidas
67 Congreso Nacional de la SEFH. Barcelona. 24-26 nov 2022

Mareque M, Climente M, Martinez-Moragon E, Padilla A, Oyagüez I, Touron C, Torres C, Martinez A

 

 

Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain
J Asthma. 2023;60(6):1210-1220

Córdoba R, López-Corral L, Presa M, Martín-Escudero V, Casado MÁ, Pardo C

 

 

Value of Axicabtagene Ciloleucel Versus Chemotherapy in the Large B-Cell Lymphoma Treatment: Health Outcomes Based on the Number of Patients Treated in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022

POSTER

Presa M, Vicente D, Calles A, Salinas-Ortega L, Naik J, García LF, Soto J

 

 

Lorlatinib as a first-line treatment for ALK+ advanced Non-Small Cell Lung Cancer: a cost-effectiveness analysis in Spain
25th Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Viena (Austria). 06-09 nov 2022

POSTER